Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,298 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Response Clear all

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Not interventional; Other
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, Neoplasm Metastasis
Interventions: gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis; Drug · Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
Interventions: Severe Sepsis Management Bundle; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 1 Month to 18 Years
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Myocardial Ischemia
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obsessive Compulsive Disorder
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Hartford Hospital; Other
Eligibility: 20 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Major Depressive Disorder
Interventions: Problem Solving Therapy; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 65 Years and older
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Specific Phobia
Interventions: Exposure therapy; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
Interventions: TR(ACE) Assay Testing; Device
Lead sponsor: Biological Dynamics; Industry
Eligibility: 21 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Encinitas, California • Oceanside, California • Santa Monica, California + 13 more

Conditions: Hereditary Angioedema (HAE)
Interventions: CINRYZE; Biological
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 95 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Controls
Interventions: Atorvastatin, Pneumovax 23, Placebo (lactose pill); Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions: Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ITP, Immune Thrombocytopenia
Interventions: Fostamatinib; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more

Conditions: Chronic Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin's Lymphoma
Interventions: Cu-64 Rituximab; Drug
Lead sponsor: Sanjiv Sam Gambhir; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rheumatoid Arthritis
Interventions: SAIT101, MabThera, Rituxan; Biological
Lead sponsor: Archigen Biotech Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Anniston, Alabama • El Cajon, California • La Mesa, California + 10 more

Conditions: HIV Infections, Tuberculosis
Interventions: Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 21
States / cities: Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more

Conditions: Candidiasis
Interventions: Micafungin, Liposomal Amphotericin B; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Not listed
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 27
States / cities: Birmingham, Alabama • Orange, California • Denver, Colorado + 19 more

Conditions: Sepsis, Severe, Septic Shock
Interventions: Smoflipid; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: HIV Infection
Interventions: Etanercept (Enbrel); Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Chronic Hepatitis C Infection
Interventions: GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Phoenix, Arizona • Anaheim, California • La Jolla, California + 29 more

Conditions: Rectal Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC

Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Electronic Application of a Severe Sepsis Screening Tool and Management Bundle

Responses of Myocardial Ischemia to Escitalopram Treatment

Neural Mechanisms of CBT Response in Hoarding Disorder

Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression

The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia

TR(ACE) Assay Clinical Specimen Study

CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12

People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)

The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23

De-Escalation Therapy for Human Papillomavirus Negative Disease

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C

Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

LIPIDS-P Trial Phase I/II Trial

Safety and Efficacy Study of Etanercept (Enbrel) on the Response Rate of HIV-infected Subjects

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer